It was reported that dual targeting of human epidermal growth factor receptor 3 (HER3) and epidermal growth factor receptor (EGFR) could overcome anti-EGFR resistance in CRC tumors [2], indicating that dual targeting therapy maybe an effective approach to overcome CRC drug resistance. This evidence concerns the gene ERBB3 and colorectal carcinoma.